Work

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”

Year: 2022

Type: article

Abstract: Core-binding factor acute myeloid leukemia (CBF-AML) has been associated with relatively better prognosis following intensive AML directed therapy, typically consisting of 7 days of continuous intravenous (IV) cytarabine and 3 days of anthracycline IV push (“7 + 3”), followed by multiple cycles of high-dose cytarabine consolidation [ 1 , 2 ]. However, such therapy has been associated with a 30–50% relapse rate [ 3 ], thus warranting consideration of alternative induction regimens including FLAG-IDA (fludarabine, cytarabine, idarubicin and filgrastim) and induction enhancements with gemtuzumab ozogamicin (GO) [ 4 , 5 , 6 , 7 ] or dasatinib [ 8 ]. Such therapeutic approaches have not been tested in a controlled setting and retrospective comparisons require examination of data from multiple sources that utilized 7 + 3 in large cohorts with long-term follow-up.

Source: Blood Cancer Journal

DOI: 10.1038/s41408-022-00654-0